Onco Wiki / drapeau rouge

AML with detectable measurable residual disease (MRD) after induction or consolidation —...

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDRF-AML-MEASURABLE-RESIDUAL-DISEASE
TypeSignal d’alerte
Étatreviewed 2026-04-27 | pending_clinical_signoff
MaladiesDIS-AML
SourcesSRC-ELN-AML-2022 SRC-NCCN-AML-2025 SRC-QUAZAR-WEI-2020

Origine du drapeau rouge

DéfinitionAML with detectable measurable residual disease (MRD) after induction or consolidation — defined per ELN 2021 MRD working-party as ≥0.1% MFC-MRD by multiparametric flow cytometry, OR molecular MRD ≥10⁻³ for NPM1/CBF/KMT2A-rearranged transcripts (RT-qPCR), OR persistent detectable WT1 transcript >2.5×10⁻³ in PB. MRD-positivity post-CR1 is the strongest single predictor of relapse (RFS hazard ratio 3-5×) and defines the population that benefits from consolidation intensification: alloHCT in CR1 (per ELN 2022) over standard HiDAC consolidation, or switch to MRD-directed maintenance (oral azacitidine post-consolidation per QUAZAR; gilteritinib post-alloHCT for FLT3-ITD per MORPHO).
Direction cliniqueintensifier
Catégoriehigh-risk-biology
Algorithme de décalageALGO-AML-1L, ALGO-AML-2L

Logique de déclenchement

{
  "any_of": [
    {
      "finding": "aml_mrd_positive",
      "value": true
    },
    {
      "finding": "aml_mrd_status",
      "value": "positive"
    },
    {
      "finding": "aml_mrd_post_induction",
      "value": "positive"
    },
    {
      "comparator": ">=",
      "finding": "mfc_mrd_percent",
      "threshold": 0.1
    },
    {
      "comparator": ">=",
      "finding": "molecular_mrd_npm1",
      "threshold": 0.001
    },
    {
      "comparator": ">",
      "finding": "wt1_transcript_pb",
      "threshold": 0.0025
    }
  ],
  "type": "biomarker"
}

Notes

Timing matters: MRD assessed after induction (cycle 1 day 28 BM) and after each consolidation cycle. MRD-positive after induction in favorable-risk (NPM1+/FLT3-ITD-WT or CBF) does not automatically mean alloHCT — repeat after consolidation; persistent or rising MRD is the trigger. Method choice: NPM1-mut → RT-qPCR for the NPM1 transcript (most sensitive, ≤10⁻⁵); CBF (RUNX1::RUNX1T1, CBFB::MYH11) → RT-qPCR for the fusion; otherwise MFC-MRD with LAIP/DfN gating (sensitivity 10⁻³ to 10⁻⁴). Emerging: error-corrected NGS for non-NPM1 mutations (DTA mutations DNMT3A/TET2/ASXL1 are clonal-hematopoiesis-related, do NOT count as MRD-positive). RF coexists with RF-AML-FLT3-ACTIONABLE (different axes; FLT3-mut + MRD-positive = strong alloHCT in CR1 + post-transplant gilteritinib maintenance per MORPHO).

Utilisé par

Algorithmes

Signal d’alerte